237 Enhancing mesothelin-directed CAR T cell therapy for unresectable or metastatic pancreatic adenocarcinoma
M. Gómez(University of Pennsylvania), Mark H. O’Hara(University of Pennsylvania), Shelley L. Berger(University of Pennsylvania), Sangya Agarwal(Amgen (United States)), Charly R. Good(University of Pennsylvania), Carl H. June(University of Pennsylvania), Wesley V. Wilson(University of Pennsylvania), Donna Gonzales(University of Pennsylvania), Regina M. Young(University of Pennsylvania), Julie K. Jadlowsky(University of Pennsylvania), Wei-Ting Hwang(University of Pennsylvania), Julie S. Barber-Rotenberg(University of Pennsylvania)
Cited by 1
Related Papers
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|799
TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision
|Immunity|2019|703
Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8
|Genes & Development|2003|699
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
|JCI Insight|2018|573